Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort

Gene

Volumn 530, Issue 2, 2013, Pages 273-277

  Srivastava, Priyanka ^a   Kapoor, Rakesh ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Haplotype; Matrix metalloproteinases; PCR RFLP; Polymorphism; Prostate cancer; Tissue Inhibitors of metalloproteinases

Indexed keywords

STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING HABIT;

DIGITAL RECTAL EXAMINATION; DRE; HAPLOTYPE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASES; MMP; PCA; PCR-RFLP; POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM; POLYMORPHISM; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN; PSA; SINGLE-NUCLEOTIDE POLYMORPHISMS; SNP; TIMP; TISSUE INHIBITORS OF METALLOPROTEINASE; TISSUE INHIBITORS OF METALLOPROTEINASES;

AGED; ALLELES; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDIA; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NEOPLASM GRADING; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84884535421     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.06.087     Document Type: Article

References (29)

1. Ahonen M., Baker A.H., Kahari V.M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998, 58:2310.
2. Langers Alexandra M.J., Verspaget Hein W, Hommes Daniel W, Sier Cornelis F.M. Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World J. Gastrointest. Oncol. 2011, 3(6):79-98.
3. Baker A.H., George S.J., Zaltsman A.B., Murphy G., Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer 1999, 79:1347-1355.
4. Bian J., et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 1996, 17:1805.
5. Boag A.H., Young I.D. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am. J. Pathol. 1994, 144:585-591.
6. Chen Q.J., Lu L., Shen W.F. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients. Clin. Chim. Acta 2009, 405:97-103.
7. Fassina G., Ferrari N., Brigati C., Benelli R., Santi L., Noonan D.M. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin. Exp. Metastasis 2000, 18:111-120.
8. Ghilardi G., et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 2002, 8:3820-3823.
9. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974, 111:58-64.
10. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74:111-122.
11. Hinoda Y., et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int. J. Cancer 2002, 102:526-529.
12. Jiang Y., Goldberg I.D., Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
13. Kodate M., Kasai T., Hashimoto H., Yasumoto K., Iwata Y., Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol. Int. 1997, 47(7):461-469. (Jul).
14. Krex D., Röhl H., König I.R., Ziegler A., Schackert H.K., Schackert G. Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms. Stroke 2003, 34(12):2817-2821. (Epub 2003 Nov 6).
15. Mannello F., Luchetti F., Falcieri E., Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005, 10:19-24.
16. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
17. Moroz A., Delella F.K., Lacorte L.M., Deffune E., Felisbino S.L. Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2013, 430(4):1319-1321. (Jan 25).
18. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
19. O'Charoenrat P., Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006, 42:257-267.
20. Peterson N.B., et al. Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival. Int. J. Cancer 2009, 125(4):844-850.
21. Qi J.H., et al. Anovel function for tissue inhibitor of metalloproteinases-3 (TIMP-3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 2003, 9:407-415.
22. Shibata N., et al. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:1011-1014.
23. Shinojima T., et al. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics 2012, 7(11):1279-1289.
24. Vairaktaris E., et al. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol. Rep. 2007, 17:963-968.
25. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
26. Yang L., et al. Tissue inhibitor of metalloproteinase-2G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. Eur. J. Surg. Oncol. 2007, 34:636-641.
27. Ye S., Watts G.F., Mandalia S., Humphries S.E., Henney A.M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br. Heart J. 1995, 73:209-215.
28. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 1996, 271:13055-13060.
29. Yoon S.O., Park S.J., Yun C.H., Chung A.S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol. 2003, 36:128-137.